| Literature DB >> 32265245 |
Xiyi Wang1, Doris Howell2, Leiwen Tang1, Jing Shao3, Zhihong Ye4.
Abstract
OBJECTIVES: In this study, we aimed to estimate the prevalence of metabolic syndrome (MetS) among Chinese adults, describe the disease components and compare utility of the existing international criteria and Chinese diagnostic criteria. DESIGN, SETTING AND PARTICIPANTS: A retrospective database analysis was conducted for one hospital in Zhejiang province, China. We analysed data (collected in 2017) from a total of 64 902 participants (37 500 males and 27 402 females), aged between 18 and 97 years, and who met the eligibility criteria. MAIN OUTCOME MEASURES: We employed three criteria for MetS proposed by the International Diabetes Federation (IDF) in 2005, the 2009 Joint Scientific Statement (harmonising criteria) and the China Diabetes Society (CDS) in 2013 to detect prevalence of MetS. Specifically, we analysed waist circumference, blood pressure, fasting plasma glucose, plasma triglycerides and plasma high-density lipoprotein cholesterol.Entities:
Keywords: cardiac epidemiology; hypertension; lipid disorders; public health
Mesh:
Year: 2020 PMID: 32265245 PMCID: PMC7245414 DOI: 10.1136/bmjopen-2019-035216
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Criteria for clinical diagnosis of metabolic syndrome
| Variables | Recommended thresholds | ||
| IDF 2005 | Harmonising criteria 2009 | CDS 2013 | |
| Abdominal obesity | ≥90 cm (male); | ≥85 cm (male); | ≥90 cm (male); |
| Triglycerides | ≥1.7 mmol/L or treatment | ≥1.7 mmol/L or treatment | ≥1.7 mmol/L |
| Plasma high-density lipoprotein cholesterol | <1.03 mmol/L (male); | <1.0 mmol/L (male); | <1.04 mmol/L |
| Blood pressure | Systolic ≥130 or diastolic ≥85 mm Hg or treatment | Systolic ≥130 and/or diastolic ≥85 mm Hg or treatment | BP ≥130/85 mm Hg or treatment |
| Fasting plasma glucose | ≥5.6 mmol/L or previously diagnosed T2DM | ≥5.6 mmol/L or treatment | ≥6.1 mmol/L, and(or) 2hPG≥7.8 mmol/L or treatment |
CDS, China Diabetes Society; IDF, International Diabetes Federation; T2DM, type 2 diabetes mellitus.
Characteristics of participants by sex (n=64 902)
| Category | Male (n=37 500) | Female (n=27 402) |
| Body mass index (kg/m2) | 24.76 (24.73 to 24.79) | 22.43 (22.39 to 22.46) |
| Waist circumference | 87.44 (87.35 to 87.53) | 75.92 (75.82 to 76.02) |
| Triglycerides (mmol/L) | 1.87 (1.85 to 1.88) | 1.20 (1.19 to 1.20) |
| HDL-cholesterol (mmol/L) | 1.13 (1.13 to 1.13) | 1.38 (1.37 to 1.38) |
| Glucose (mmol/L) | 5.38 (5.36 to 5.39) | 5.07 (5.06 to 5.08) |
| Systolic blood pressure (mm Hg) | 126.96 (126.79 to 127.13) | 118.15 (117.93 to 118.36) |
| Diastolic blood pressure (mm Hg) | 76.99 (76.88 to 77.11) | 69.78 (69.65 to 69.90) |
HDL-cholesterol, high-density lipoprotein cholesterol.
Estimated prevalence of metabolic abnormalities screened by the three criteria (N, %)
| Criteria | IDF 2005 | P | Harmonising criteria 2009 | P | CDS 2013 | P | ||||||
| Total | Male 37 500 | Female | Total | Male 37 500 | Female | Total | Male 37 500 | Female | ||||
| Increased WC | 23 387 (36.0) | 14 834 (39.6) | 8553 | <0.001 | 32 494 (50.1) | 23 941 (63.8) | 8553 | <0.001 | 19 175 (29.5) | 14 834 (39.6) | 4341 | <0.001 |
| Increased TG | 32 140 (49.5) | 21 559 | 10 581 | <0.001 | 32 140 (49.5) | 21 559 (57.5) | 10 581 (38.6) | <0.001 | 19 796 | 15 267 | 4529 | <0.001 |
| Reduced HDL-C | 27 012 (41.6) | 15 249 | 11 763 | <0.001 | 25 514 (39.3) | 13 410 | 12 104 (44.2) | <0.001 | 19 726 | 15 905 | 3821 | <0.001 |
| Increased BP | 30 386 (46.8) | 20 845 | 9541 | <0.001 | 30 386 | 20 845 | 9541 | <0.001 | 22 043 (34.0) | 15 589 | 6454 | <0.001 |
| Increased FPG | 12 986 (20.0) | 9246 | 3740 | <0.001 | 12 986 (20.0) | 9246 | 3740 | <0.001 | 7233 (11.1) | 5338 | 1895 | <0.001 |
| MetS | 16 765 (25.8) | 11 308 | 5457 | <0.001 | 24 643 | 17 828 | 6815 | <0.001 | 13 360 | 11 294 | 2066 | <0.001 |
BP, blood pressure; CDS, China Diabetes Society; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; MetS, metabolic syndrome; TG, triglycerides; WC, waist circumference.
Estimated prevalence of MetS relating to abdominal obesity by three criteria (N, %)
| Criteria | BMI | P | |||
| Underweight | Normal weight | Overweight | Obesity | ||
| IDF 2005 | 2 (0.1) | 2028 (6.2) | 9519 (41.5) | 5216 (80.2) | <0.001 |
| Harmonising criteria 2009 | 57 (2.2) | 5851 (17.8) | 13 477 (58.8) | 5258 (80.8) | <0.001 |
| CDS 2013 | 13 (0.5) | 1912 (5.8) | 7324 (31.9) | 4111 (63.2) | <0.001 |
BMI, body mass index; CDS, China Diabetes Society; IDF, International Diabetes Federation; MetS, metabolic syndrome.
Adjusted prevalence of metabolic syndrome by the three criteria by sex and age
| Category | Sample | % (95%CI) | ||
| IDF 2005 | Harmonising criteria 2009 | CDS 2013 | ||
| Overall | 64 902 | 20.4 (20.0 to 20.8) | 30.0 (29.7 to 30.4) | 16.3 (16.0 to 16.6) |
| Sex | ||||
| Male | 37 500 | 15.3 (14.8 to 15.8) | 24.0 (23.6 to 24.4) | 15.2 (14.8 to 15.8) |
| Female | 27 402 | 9.8 (9.4 to 10.2) | 12.3 (12.0 to 12.7) | 3.7 (3.5 to 3.9) |
| χ2 | 866.551 | 3455.032 | 4937.018 | |
| P value | <0.001 | <0.001 | <0.001 | |
| Age | ||||
| 18–29 | 7515 | 1.9 (1.6 to 2.2) | 3.0 (2.6 to 3.4) | 1.4 (1.1 to 1.7) |
| 30–39 | 16 319 | 2.6 (2.3 to 2.9) | 4.0 (3.7 to 4.3) | 2.1 (1.9 to 2.3) |
| 40–49 | 18 977 | 4.3 (4.0 to 4.6) | 6.5 (6.2 to 6.9) | 3.7 (3.4 to 4.0) |
| 50–59 | 14 696 | 4.4 (4.0 to 4.8) | 6.3 (5.9 to 6.7) | 3.5 (3.2 to 3.8) |
| ≥60 | 7395 | 6.1 (5.5 to 6.7) | 8.3 (7.7 to 9.0) | 4.2 (3.7 to 4.7) |
| χ2 | 4280.676 | 6104.856 | 2722.093 | |
| P value | <0.001 | <0.001 | <0.001 | |
CDS, China Diabetes Society; IDF, International Diabetes Federation.
Comparisons of clinical characteristics of participants with metabolic syndrome by three criteria (mean, SD)
| Male | Female | P value | |||||
| IDF 2005 | Harmonising criteria 2009 | CDS 2013 | IDF 2005 | Harmonising criteria 2009 | CDS 2013 | ||
| Age | 47.93 (11.44) | 47.83 (11.51) | 48.29 (11.00) | 53.92 (11.41) | 53.36 (11.31) | 55.50 (11.01) | 0.970 |
| BMI | 27.51 (2.54) | 26.31 (2.75) | 26.94 (2.79) | 25.78 (2.78) | 25.07 (2.98) | 26.21 (3.19) | 0.636 |
| WC | 96.08 (5.43) | 92.18 (6.91) | 94.10 (6.86) | 87.06 (6.21) | 84.61 (7.65) | 88.14 (8.00) | 0.869 |
| TG | 2.57 (2.06) | 2.49 (1.98) | 2.86 (2.17) | 1.87 (1.14) | 1.88 (1.13) | 2.48 (1.35) | 0.529 |
| HDL-C | 1.01 (0.23) | 1.02 (0.24) | 0.97 (0.20) | 1.19 (0.27) | 1.19 (0.27) | 1.06 (0.23) | 0.681 |
| SBP | 133.89 (16.55) | 133.07 (16.74) | 134.07 (17.35) | 134.03 (19.83) | 133.49 (19.95) | 138.22 (20.84) | 0.270 |
| DBP | 82.02 (11.50) | 81.29 (11.43) | 82.42 (11.91) | 76.81 (11.56) | 76.66 (11.67) | 79.34 (12.39) | 0.829 |
| FPG | 5.85 (1.65) | 5.79 (1.61) | 5.97 (1.83) | 5.61 (1.28) | 5.61 (1.69) | 6.04 (1.70) | 0.212 |
P value<0.05.
BMI, body mass index; CDS, China Diabetes Society; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference.
Agreement of the three criteria
| Criteria | Male (n=37 500) | Female (n=27 402) | Total (n=64 902) | |||
| Number | % | Number | % | Number | % | |
| CDS 2013 vs IDF 2005 | ||||||
| (+) (+) | 9093 | 24.2 | 1800 | 6.6 | 10 893 | 16.8 |
| (+) (−) | 2201 | 5.9 | 266 | 1.0 | 2467 | 3.8 |
| (−) (+) | 2215 | 5.9 | 3657 | 13.3 | 5872 | 9.0 |
| (−) (−) | 23 991 | 64.0 | 21 679 | 79.1 | 45 670 | 70.4 |
| Kappa value, 95% CI | 0.720* (0.712 to 0.728) | 0.414* (0.400 to 0.428) | 0.641* (0.633 to 0.649) | |||
| CDS 2013 vs harmonising criteria 2009 | ||||||
| (+) (+) | 10 968 | 29.2 | 2066 | 7.5 | 13 034 | 20.1 |
| (+) (−) | 326 | 0.9 | 0 | 0 | 326 | 0.5 |
| (−) (+) | 6860 | 18.3 | 4749 | 17.3 | 11 609 | 17.9 |
| (−) (−) | 19 346 | 51.6 | 20 587 | 75.1 | 39 933 | 61.5 |
| Kappa value, 95% CI | 0.609* (0.601 to 0.617) | 0.395* (0.383 to 0.407) | 0.572* (0.566 to 0.578) | |||
| IDF 2005 vs harmonising criteria 2009 | ||||||
| (+) (+) | 11 061 | 29.5 | 5457 | 19.9 | 16 518 | 25.5 |
| (+) (−) | 247 | 0.7 | 0 | 0 | 247 | 0.4 |
| (−) (+) | 6767 | 18.0 | 1358 | 5.0 | 8125 | 12.5 |
| (−) (−) | 19 425 | 51.8 | 20 587 | 75.1 | 40 012 | 61.6 |
| Kappa value, 95% CI | 0.618* (0.610 to 0.626) | 0.858* (0.850 to 0.866) | 0.708* (0.702 to 0.714) | |||
The differences between every two criteria were evaluated by χ2 test. ‘+’ means that patient was diagnosed as metabolic syndrome by the given criteria; ‘−’ means that patient was no metabolic syndrome by the given criteria.
*P value<0.001.
CDS, China Diabetes Society; IDF, International Diabetes Federation.